Cardiff Oncology Inc (NASDAQ: CRDF) on Friday, plunged -4.36% from the previous trading day, before settling in for the closing price of $3.44. Within the past 52 weeks, CRDF’s price has moved between $2.01 and $6.38.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 24.32% over the past five years. The company achieved an average annual earnings per share of 16.14%. With a float of $59.79 million, this company’s outstanding shares have now reached $66.52 million.
Let’s look at the performance matrix of the company that is accounted for 33 employees. In terms of profitability, gross margin is 69.74%, operating margin of -7112.72%, and the pretax margin is -6642.84%.
Cardiff Oncology Inc (CRDF) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cardiff Oncology Inc is 10.13%, while institutional ownership is 34.43%. The most recent insider transaction that took place on Dec 17 ’24, was worth 14,905. In this transaction Chief Financial Officer of this company bought 2,752 shares at a rate of $5.42, taking the stock ownership to the 65,316 shares. Before that another transaction happened on Dec 18 ’24, when Company’s Chief Financial Officer bought 2,400 for $5.00, making the entire transaction worth $12,000. This insider now owns 67,716 shares in total.
Cardiff Oncology Inc (CRDF) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 16.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -7.72% during the next five years compared to 19.36% growth over the previous five years of trading.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
Cardiff Oncology Inc (CRDF) is currently performing well based on its current performance indicators. A quick ratio of 7.08 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 321.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.95, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.95 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
Cardiff Oncology Inc (NASDAQ: CRDF) saw its 5-day average volume 0.87 million, a negative change from its year-to-date volume of 1.11 million. As of the previous 9 days, the stock’s Stochastic %D was 5.79%. Additionally, its Average True Range was 0.29.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 30.48%, which indicates a significant increase from 2.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 85.37% in the past 14 days, which was lower than the 135.78% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.98, while its 200-day Moving Average is $3.09. Nevertheless, the first resistance level for the watch stands at $3.42 in the near term. At $3.55, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.63. If the price goes on to break the first support level at $3.21, it is likely to go to the next support level at $3.13. The third support level lies at $3.00 if the price breaches the second support level.
Cardiff Oncology Inc (NASDAQ: CRDF) Key Stats
Market capitalization of the company is 218.86 million based on 66,524K outstanding shares. Right now, sales total 680 K and income totals -45,430 K. The company made 150 K in profit during its latest quarter, and -11,790 K in sales during its previous quarter.
